January 19th 2023
Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.
NSAIDs May Be Safe for Use in Hemophilia, but More Research Is Needed
November 11th 2022The hesitation to prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with hemophilia is not supported by current research, based on a recently published review, but the available studies had significant limitations.
Read More
Cost-Savings Model Estimates Reduced Economic Burden With Gene Therapy for Hemophilia A
November 6th 2022Gene therapy is a novel approach to hemophilia A treatment that carries a substantial cost up front but may lead to cost savings compared with current prophylaxis agents in the long run.
Read More
ICER Releases Draft Evidence Report on Gene Therapies for Hemophilia A and B
September 17th 2022Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.
Read More
Review Looks at Impact of SDOH on Bleeding Disorders
September 9th 2022More than 3 million Americans have inherited bleeding disorders, and social determinants of health (SDOH) play a role in a number of ways, including cost for treatment, difficulty accessing specialists, educational barriers, and more.
Read More
Case Study Chronicles Onset and Treatment of Acquired Hemophilia A Following HSCT for ALL
September 6th 2022The case emphasizes the importance for clinician awareness of the potential for rare immune-mediated disorders, including acquired hemophilia A (AHA), following allogeneic hematopoietic stem cell transplantation (HSCT).
Read More
Systematic Approaches to Patient Educational Needs May Benefit Those With Bleeding Disorders
September 2nd 2022Nurse-led education is an essential aspect of care for patients with bleeding disorders, but there is currently a lack of research on specific strategies to improve patient self-management through education.
Read More
Gaps Remain Between European Regions for Hemophilia Care Despite Improvements
July 17th 2020Hemophilia care principles have been on the rise in Europe over the course of the last decade, however, differing regions and policies on the continent reveal gaps in access to various treatments and specialty services.
Read More
Prevalence of Hemophilia Worldwide Is Triple That of Previous Estimates, New Study Says
September 10th 2019The meta-analysis showed that more than 1,125,000 men around the world have the inherited bleeding disorder; 418,000 of those have a severe version of the mostly undiagnosed disease. Previously, only 400,000 people globally were estimated to have hemophilia.
Read More